Practice Statements - ALA

Practice Statements

During 2026 the ALA will continue to formulate Consensus Practice Statements for diagnosis and management of key lymphoma subtypes, while also updating previously published Statements. These will be developed in collaboration with the ALLG, with consultation requested from HSANZ.

Please find information on complete statements below:

Diagnosis and management of mantle cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

Diagnosis, management and follow-up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance

Chronic lymphocytic leukaemia Australasian consensus practice statement

Diagnosis and management of primary central nervous system lymphoma: a Consensus Practice Statement from the Australasian Lymphoma Alliance

Diagnosis, management and follow up of peripheral T cell lymphomas: A Consensus Practice Statement from the Australasian Lymphoma Alliance

Diffuse large B-cell lymphoma: A consensus practice statement from the Australasian Lymphoma Alliance

Assessment and Management of Newly Diagnosed Classical Hodgkin Lymphoma: A Consensus Practice Statement from the Australasian Lymphoma Alliance

Australia & New Zealand Consensus Position Statement: COVID-19 Vaccination in Haematology Patients

Australian Clinical Practice Statement: Mycosis Fungoides and Sezary Syndrome

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic

If you are interested in participating in or supporting the development of future practice statements please contact the ALA Administration Manager.

ALAadmin@snowdome.org.au